TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Benzinga Logo Benzinga By Vandana Singh
DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina reported strong Q3 earnings, beating expectations with $1.34 per share, driven by clinical market momentum. The company raised fiscal 2025 earnings guidance and saw positive performance in instrument placements.

Insights
META   negative

Faced pressure over rising capital expenditures and delayed return on investment


ILMN   positive

Exceeded earnings expectations, raised fiscal guidance, reported growth in clinical markets, and saw stock price increase of 21.7%